Medical and Biological Laboratories Corporation

Ina, Japan

Medical and Biological Laboratories Corporation

Ina, Japan

Time filter

Source Type

Patent
Sapporo Medical University, Medical and Biological Laboratories Co. | Date: 2017-08-02

The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.


Patent
Microbial Chemistry Research Foundation, Medical and Biological Laboratories Co. | Date: 2015-03-18

An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.


Patent
Osaka University and Medical And Biological Laboratories Co. | Date: 2013-01-31

Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.


It has been found out that among antibodies showing reactivity with wild type TGF-, antibodies less reactive with G79A-substituted TGF- have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.


Patent
Tokai University, Tokyo Metropolitan Institute of Medical Science, Renascience CO., Medical and Biological Laboratories Co. | Date: 2013-11-13

The present invention relates to a method for diagnosing schizophrenia comprising measuring at least one parameter in a subject, the parameter being selected from the group consisting of (1) a genetic abnormality of glyoxalase I gene, (2) the expression level or activity of glyoxalase I in a biological sample, (3) the amount of a carbonyl-modified protein that is a protein modified with the carbonyl-compound, preferably pentosidine, in a biological sample, and (4) the amount of pyridoxal in a biological sample. The present further relates to a primer, a probe and a reagent for use in said method, as well as an AGE-reader and its use for measuring the amount of carbonyl-modified proteins.


Patent
Nagoya University, Medical, Biological Laboratories Co. and Oncomics Co. | Date: 2014-07-23

To develop a simple, low-cost and highly reliable testing method for mesothelioma, and a kit used for said testing method. The present invention provides a testing method for mesothelioma comprising a step in which the concentration of human periostin protein is measured in at least one type of sample from among samples of the blood or pleural fluid of a subject. The step in which the concentration of human periostin protein is measured may use an antibody directed against human periostin protein. The present invention further provides a kit for diagnosing mesothelioma, said kit including the antibody directed against human periostin protein. In one kit for diagnosing mesothelioma, the diagnosis of mesothelioma determines if a subject that may have mesothelioma has mesothelioma or is healthy. In another kit for diagnosing mesothelioma, the diagnosis of mesothelioma determines if a subject that may have mesothelioma has mesothelioma or has a respiratory illness other than mesothelioma.


Patent
Medical and Biological Laboratories Co. | Date: 2014-10-15

A method for detecting an interaction between a first protein and a second protein comprises the steps of:expressing in a cell a first fusion protein comprising the first protein and an association-inducing protein, and a second fusion protein comprising the second protein and a fluorescent protein having a multimerization ability;detecting a fluorescent focus formed by an association between the first fusion protein and the second fusion protein in the cell; anddetermining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.


Patent
Riken, Medical and Biological Laboratories Co. | Date: 2011-04-27

The present invention refers to a fluorescent protein described in the following (a) or (b):(a) a protein having the amino acid sequence shown in SEQ ID NO: 41; or(b) a protein, which has an amino acid sequence comprising a deletion, substitution,and/or addition of one to 10 amino acids with respect to the amino acid sequence shown in SEQ ID NO: 41, which has fluorescence properties, and which has a stokes shift of 100 nm or greater.


Patent
Medical and Biological Laboratories Co. | Date: 2011-04-27

The present invention refers to a fluorescent protein having either one of the following amino acid sequences:(a) an amino acid sequence shown in SEQ ID NO: 9; or(b) an amino acid sequence comprising a deletion, substitution and/or addition of 1 to 20 amino acids with respect to the amino acid sequence shown in SEQ ID NO: 9, and having fluorescent properties.


Patent
Riken, Medical and Biological Laboratories Co. | Date: 2011-04-27

The present, invention refers to a fluorescent protein having either one of the following amino acid sequences:(a) an amino acid sequence shown in SEQ ID NO: 5; or(b) an amino acid sequence comprising a deletion, substitution and/or addition of I to 20 amino acids with respect to the amino acid sequence shown in SEQ ID NO: 5, and having fluorescent properties;and to a. fluorescent protein having an amino acid sequence shown in SEQ ID NO:7.

Loading Medical and Biological Laboratories Corporation collaborators
Loading Medical and Biological Laboratories Corporation collaborators